- Home
- RSF vs ATRA Comparison
RSF vs ATRA Comparison
Compare RSF & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- ATRA
- Stock Information
- Founded
- RSF 2016
- ATRA 2012
- Country
- RSF United States
- ATRA United States
- Employees
- RSF N/A
- ATRA N/A
- Industry
- RSF Investment Managers
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RSF Finance
- ATRA Health Care
- Exchange
- RSF Nasdaq
- ATRA Nasdaq
- Market Cap
- RSF 53.1M
- ATRA 42.9M
- IPO Year
- RSF N/A
- ATRA 2014
- Fundamental
- Price
- RSF $15.17
- ATRA $7.27
- Analyst Decision
- RSF
- ATRA Buy
- Analyst Count
- RSF 0
- ATRA 5
- Target Price
- RSF N/A
- ATRA $17.75
- AVG Volume (30 Days)
- RSF 11.8K
- ATRA 45.8K
- Earning Date
- RSF 01-01-0001
- ATRA 05-20-2025
- Dividend Yield
- RSF 10.61%
- ATRA N/A
- EPS Growth
- RSF N/A
- ATRA N/A
- EPS
- RSF N/A
- ATRA N/A
- Revenue
- RSF N/A
- ATRA $128,940,000.00
- Revenue This Year
- RSF N/A
- ATRA N/A
- Revenue Next Year
- RSF N/A
- ATRA N/A
- P/E Ratio
- RSF N/A
- ATRA N/A
- Revenue Growth
- RSF N/A
- ATRA 1404.02
- 52 Week Low
- RSF $14.81
- ATRA $5.01
- 52 Week High
- RSF $16.23
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- RSF 49.67
- ATRA 53.01
- Support Level
- RSF $15.10
- ATRA $6.90
- Resistance Level
- RSF $15.36
- ATRA $8.65
- Average True Range (ATR)
- RSF 0.11
- ATRA 0.63
- MACD
- RSF -0.00
- ATRA 0.03
- Stochastic Oscillator
- RSF 34.93
- ATRA 44.58
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).